Wat is de prijs voor MBX Biosciences, Inc. Common Stock (MBX)

Het prijs van MBX Biosciences, Inc. Common Stock (MBX) is $67.63

Wat is de marktkapitalisatie voor MBX Biosciences, Inc. Common Stock (MBX)

Marktkapitalisatie voorMBX Biosciences, Inc. Common Stock (MBX) is $3.22B

MBX Biosciences, Inc. Common Stock (MBX) Prijsgeschiedenis

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

Jaar	Prestaties
2026 (TTM)	11.16%
2025	51.62%
2024	0.00%

Jaar

Prestaties

2026 (TTM)

11.16%

2025

51.62%

2024

0.00%

Bedrijf	Aandelenkoers	Verandering 1jr%	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$549.38	41.20%	US
Argenx SE ARGX.US	$1.05K	47.75%	NL
Moderna, Inc. MRNA.US	$148.35	491.02%	US
CSL Limited CSL.AX	$121.77	-13.26%	AU
Lonza Group AG LONN.SW	$764.47	7.08%	CH

Bedrijf

Aandelenkoers

Verandering 1jr%

Land